JP2023512450A5 - - Google Patents

Info

Publication number
JP2023512450A5
JP2023512450A5 JP2022542652A JP2022542652A JP2023512450A5 JP 2023512450 A5 JP2023512450 A5 JP 2023512450A5 JP 2022542652 A JP2022542652 A JP 2022542652A JP 2022542652 A JP2022542652 A JP 2022542652A JP 2023512450 A5 JP2023512450 A5 JP 2023512450A5
Authority
JP
Japan
Prior art keywords
sequence
seq
amino acid
heavy chain
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542652A
Other languages
English (en)
Japanese (ja)
Other versions
JP7870250B2 (ja
JP2023512450A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/013200 external-priority patent/WO2021146256A1/en
Publication of JP2023512450A publication Critical patent/JP2023512450A/ja
Publication of JP2023512450A5 publication Critical patent/JP2023512450A5/ja
Application granted granted Critical
Publication of JP7870250B2 publication Critical patent/JP7870250B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542652A 2020-01-13 2021-01-13 抗trem2抗体及びその使用方法 Active JP7870250B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062960663P 2020-01-13 2020-01-13
US62/960,663 2020-01-13
US202063070728P 2020-08-26 2020-08-26
US63/070,728 2020-08-26
US202063091717P 2020-10-14 2020-10-14
US63/091,717 2020-10-14
PCT/US2021/013200 WO2021146256A1 (en) 2020-01-13 2021-01-13 Anti-trem2 antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023512450A JP2023512450A (ja) 2023-03-27
JP2023512450A5 true JP2023512450A5 (cg-RX-API-DMAC7.html) 2024-01-22
JP7870250B2 JP7870250B2 (ja) 2026-06-04

Family

ID=74587108

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542652A Active JP7870250B2 (ja) 2020-01-13 2021-01-13 抗trem2抗体及びその使用方法

Country Status (17)

Country Link
US (1) US20220177576A1 (cg-RX-API-DMAC7.html)
EP (1) EP4090682A1 (cg-RX-API-DMAC7.html)
JP (1) JP7870250B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220131246A (cg-RX-API-DMAC7.html)
CN (1) CN115279790A (cg-RX-API-DMAC7.html)
AU (1) AU2021208482B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022013756A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166385A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001886A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022009744A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22054464A (cg-RX-API-DMAC7.html)
IL (1) IL294655A (cg-RX-API-DMAC7.html)
MX (1) MX2022008582A (cg-RX-API-DMAC7.html)
PE (1) PE20221465A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551650A1 (cg-RX-API-DMAC7.html)
TW (1) TWI890727B (cg-RX-API-DMAC7.html)
WO (1) WO2021146256A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
MX2024010324A (es) 2022-02-23 2024-08-30 Alector Llc Metodos de uso de anticuerpos anti-trem2.
EP4499693A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
EP4499695A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2024253424A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도
WO2024253420A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간 항체 및 이의 용도
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
WO2026062582A1 (en) * 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies
WO2026062585A1 (en) * 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
EA201790342A1 (ru) * 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
JP7725185B2 (ja) * 2015-10-06 2025-08-19 アレクトル エルエルシー 抗trem2抗体及びその使用方法
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
EP4628586A3 (en) 2017-02-17 2026-01-14 Denali Therapeutics Inc. Transferrin receptor transgenic models
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
HUE062436T2 (hu) 2017-08-03 2023-11-28 Alector Llc Anti-trem2 antitestek és alkalmazási módszereik
WO2019055841A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
CN113302206A (zh) 2018-11-26 2021-08-24 戴纳立制药公司 治疗脂质代谢失调的方法
JP7543290B2 (ja) * 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法

Similar Documents

Publication Publication Date Title
JP2022520868A5 (cg-RX-API-DMAC7.html)
JP2021527656A5 (cg-RX-API-DMAC7.html)
JP7046804B2 (ja) 改良された血清アルブミン結合剤
US20200216522A1 (en) Anti-tau antibodies and methods of use thereof
JP2016147902A5 (cg-RX-API-DMAC7.html)
JP2020534277A5 (cg-RX-API-DMAC7.html)
JP2021533779A5 (cg-RX-API-DMAC7.html)
JP7772715B2 (ja) 治療用musk抗体
RU2008129787A (ru) Фармацевтические композиции с устойчивостью к растворимому сеа
JP2021534220A5 (cg-RX-API-DMAC7.html)
HUE025684T2 (en) Immunotherapy regimen dependent on ApoE status
CN115298214A (zh) 用于靶向淀粉样蛋白沉积物的经修饰的免疫球蛋白
HRP20192267T1 (hr) Terapeutski agens ili profilaktički agens za demenciju
JP2022529344A (ja) 治療及び診断のための新規分子
JP7797203B2 (ja) 抗gal9免疫阻害性結合分子
US20230074436A1 (en) Anti-alpha-synuclein antibodies and methods of use thereof
TW202219068A (zh) 包含il—12及抗fap抗體的融合蛋白及其用途
CN116368153A (zh) Zip12抗体
US20260109761A1 (en) Zip12 antibody
KR102862890B1 (ko) Aimp2 및/또는 aimp2 응집체에 특이적으로 결합하는 항체
WO2022103660A1 (en) Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
JP2024543942A5 (cg-RX-API-DMAC7.html)